Cargando…

A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study

OBJECTIVE: To compare the efficacy of agomelatine with escitalopram in the treatment of major depressive disorder (MDD), improve sleep in MDD patients and study the adverse effects of agomelatine. MATERIALS AND METHODS: Randomized, parallel-group, open-label study. The primary efficacy outcome was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urade, Chetan S., Mahakalkar, Sunil M., Tiple, Prashant G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714386/ https://www.ncbi.nlm.nih.gov/pubmed/26813706 http://dx.doi.org/10.4103/0976-500X.171883

Ejemplares similares

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

Randomized controlled comparison of agomelatine and escitalopram: Concerns about study design and methods
por: Pal, Sutanaya, et al.
Publicado: (2016)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak, Jan, et al.
Publicado: (2013)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report
por: De Berardis, Domenico, et al.
Publicado: (2012)

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
por: Gahr, Maximilian
Publicado: (2014)

N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study
por: Mahakalkar, Sunil M., et al.
Publicado: (2017)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Agomelatine for postpartum depression and breastfeeding
por: Xiao, Le
Publicado: (2021)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder
por: Huang, Juan, et al.
Publicado: (2023)

Efficacy and tolerability of agomelatine in the treatment of depression
por: Plesničar, Blanka Kores
Publicado: (2014)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2023)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis
por: Guo, Yue-Han, et al.
Publicado: (2023)

Agomelatine and its therapeutic potential in the depressed patient
por: Kennedy, Sidney H, et al.
Publicado: (2007)

Agomelatine: The evidence for its place in the treatment of depression
por: Eser, Daniela, et al.
Publicado: (2010)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
por: De Berardis, Domenico, et al.
Publicado: (2015)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study
por: Hsing, Shih-Chun, et al.
Publicado: (2020)

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang, Gang, et al.
Publicado: (2018)

Agomelatine: relief ensured at each and every stage of depression
por: Möller, Hans-Jurgen
Publicado: (2010)

The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study
por: Gorwood, Philip, et al.
Publicado: (2020)

Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study
por: Ivanov, Stanislav V, et al.
Publicado: (2014)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Parallel Changes in Mood and Melatonin Rhythm Following an Adjunctive Multimodal Chronobiological Intervention With Agomelatine in People With Depression: A Proof of Concept Open Label Study
por: Robillard, Rebecca, et al.
Publicado: (2018)

Sertraline versus escitalopram in South Asians with moderate to severe major depressive disorder: (SOUTH-DEP) a double-blind, parallel, randomized controlled trial
por: Raza, Sidra, et al.
Publicado: (2023)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Howland, Robert H
Publicado: (2009)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vi4q3t8st0gt9r65ku7av9627